RETINITIS PIGMENTOSA

This study tests a new gene therapy called CPK850 for people with a rare form of retinitis pigmentosa caused by mutations in the RLBP1 gene. The therapy is injected under the retina to replace the faulty gene. The main goals are to check safety and see if it helps the eye adjust …

This program provides OCU400, an experimental treatment, to up to 75 adults with retinitis pigmentosa who cannot join the main Phase 3 trial. The goal is to offer access to those with no other FDA-approved options. Participants must have a confirmed genetic diagnosis and evidence…

This study tests a gene therapy called OCU400 for people with retinitis pigmentosa, an inherited eye disease that causes vision loss. The trial enrolled 140 participants aged 3 and older. The main goal is to see if the treatment improves the ability to navigate a maze in dim ligh…

This early-stage study tests the safety of a single injection of RTx-015 into the eye for adults with retinitis pigmentosa or choroideremia, two inherited conditions that cause progressive vision loss. About 18 participants will receive one of four dose levels and be monitored fo…

This phase 3 trial tests whether an oral antioxidant called N-acetylcysteine (NAC) can slow the loss of vision in people with retinitis pigmentosa, an inherited eye disease that causes blindness. About 485 adults aged 18 to 65 will take NAC or a placebo daily for 45 months. The s…

This study tests a gene therapy for Japanese people with X-linked retinitis pigmentosa, a genetic condition that causes gradual vision loss. The treatment delivers a working gene to the retina using a harmless virus. The main goals are to check safety and see if it can slow or im…

This study looks at the long-term safety of an antioxidant called N-Acetylcysteine (NAC) in 30 adults with retinitis pigmentosa, a genetic eye disease that leads to vision loss and blindness. Participants take NAC tablets twice a day for up to 12 months. The goal is to see if NAC…

This early-stage study tests whether it is safe to take a person's own bone marrow stem cells and inject them into the eye to treat blindness caused by diseases like macular degeneration and diabetic retinopathy. Fifteen adults with severe vision loss will receive the injection a…

This study tests a treatment called transcorneal electrical stimulation in 21 adults with retinitis pigmentosa, a condition that causes vision loss. The goal is to see if this therapy can improve visual field and sharpness. Participants receive the stimulation and are followed fo…

This study follows 103 adults with retinitis pigmentosa caused by EYS gene mutations over 4 years. Researchers measure changes in vision, retinal sensitivity, and eye structure to understand how the disease naturally progresses. The goal is to develop better ways to test future t…

This study follows 44 people with a rare genetic eye condition called PCDH15-related Usher syndrome. Researchers measure how vision changes over 4 years using eye tests and scans. No treatment is given; the goal is to understand the disease better so future clinical trials can be…

This study follows 50 people with a genetic eye condition called PRPF31-related retinal dystrophy (RP11) to understand how their vision changes over time. Researchers will measure things like visual sharpness, retinal thickness, and daily function using eye exams and patient ques…

This study follows 12 adults with severe retinitis pigmentosa (RP), an inherited eye disease that causes vision loss. The goal is to find out which vision tests people with low eyesight can reliably perform and how their vision declines over one year. Participants do not receive …

This study looks at 40 people with a rare eye disease called retinitis pigmentosa. Researchers are testing new ways to measure how the disease changes the eye over time. The goal is to find better tools for future studies that test treatments. No drugs or treatments are given in …